916993-73-2

Upstream product

• 3490-06-0 N-methylhomoveratrylamine 
• 107-13-1 acrylonitrile 
• 542-76-7 3-Chloropropionitrile 

Downstream Products

• 55982-99-5 1-[N-methyl-N-(2(3,4-dimethoxy-phenyl)-ethyl)-amino]-3-aminopropane 
• 916993-78-7 2-amino-N-{3-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]propyl}benzamide 
• 127405-68-9 (E)-N-<3--N'-methyl>aminopropyl>-4-(4-methylthiophenyl)-3-butenamide 
• 127405-70-3 4-[(E)-3-(3-{[2-(3,4-Dimethoxy-phenyl)-ethyl]-methyl-amino}-propylcarbamoyl)-propenyl]-benzoic acid methyl ester 

Relevant academic research and scientific papers

In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450

Synthesis and in vitro cytotoxicity assays of new anthranilamide MDR modulators have been performed to assess their inhibition potency of the P-glycoprotein (P-gp) transporter. The aromatic spacer group between nitrogen atoms (N1 and N2/s

Synthesis and cardiovascular activity of phenylalkylamine derivatives. I. Potential specific bradycardic agents

A series of acyclic amide derivatives of N-(ω-aminoalkyl)-N-methylhomoveratrylamine was synthesized and evaluated for their bradycardic activity in isolated guinea pig right atria. Among these compounds, (E)-N-[3[N'-[2-(3,4-dimethoxyphenyl)ethyl]-N'-methy